Morocco medicine price database

GLIVEC

IMATINIB

Public price

20.399,00 MAD

Reimbursement base

3.800,00 MAD

Active substance

IMATINIB

Reimbursable

What is this medicine?

Imatinib mesylate is a kinase inhibitor indicated for the treatment of various types of leukemia, myeloproliferative diseases, and specific stromal tumors.

Verified summary

IMATINIB, GELULE, 100 MG, 1 BOITE 120 GELULE

Common uses

Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML),Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL),Myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements,Aggressive systemic mastocytosis (ASM),Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL),Unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP),Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST),Adjuvant treatment following resection of Kit (CD117) positive GIST

Class

kinase inhibitor

Availability note

Reimbursable

Hospital price

20.007,00 MAD

Strength

100 MG

Form

GELULE

Presentation

1 BOITE 120 GELULE

Type

P

Therapeutic class

ANTINEOPLASIQUE CYTOTOXIQUE

This information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.

Price history

Reference price recorded since 2017-12-18: 20.399,00 MAD

Available presentations and strengths

Medicines with the same active substance